2023年6月7日 · Best practices for distinguishing IHC 0 vs 1+ include using ASCO/CAP recommended scoring critieria, reviewing at 40x to detect faint or focal areas of expression, …

2023年6月7日 · To update ASCO–College of American Pathologists (CAP) recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. The Panel is …

2023年6月7日 · Dr. Antonio Wolff and Dr. Kim Allison discuss the latest ASCO-CAP guideline update on HER2 testing in breast cancer. This guideline update affirms previous …

2023年6月7日 · This algorithm is derived from recommendations in Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-CAP Guideline Update. This is a tool …

2018年6月19日 · First released in 2007 and updated in 2013, the recommendations by the ASCO/College of American Pathologists Human Epidermal Growth Factor Receptor 2 (HER2) …

All newly diagnosed patients with breast cancer must have a HER2 test performed. Patients who then develop metastatic disease must have a HER2 test performed in a metastatic site, if …

IHC expression for HER2 should be used to complement ISH and define HER2 status. If the IHC result is not 3+ positive, it is recommended that the specimen be considered HER2 negative …

If the case has an average HER2 signals per tumor cell of $ 4.0 and , 6.0 and the HER2/CEP17 ratio is , 2.0, formerly diagnosed as ISH equivocal for HER2, a definitive diagnosis will be …

ASCO and the CAP first published evidence-based clinical practice guidelines on HER2 testing in breast cancer in 2007,1 and updated the guideline in 20132 and 2018.3 This update assesses …

therapy requires a HER2-positive test result, additional HER2 testing should be attempted in equivocal specimens to attempt to obtain a positive or negative HER2 test result and most …